Cell Engineering and Molecular Pharming for Biopharmaceuticals

Biopharmaceuticals are often produced by recombinant E. coli or mammalian cell lines. This is usually
achieved by the introduction of a gene or cDNA coding for the protein of interest into a well-characterized strain of producer
cells. Naturally, each recombinant production system has its own unique advantages and disadvantages. This paper
examines the current practices, developments, and future trends in the production of biopharmaceuticals. Platform technologies
for rapid screening and analyses of biosystems are reviewed. Strategies to improve productivity via metabolic
and integrated engineering are also highlighted.